SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

Summary

This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.

Timeline

Start

2024-07-29

Primary completion

2026-04-08

Completion

2026-04-08

Drugs

Indications